FPRX Stock News 13.64 05/09/2014 19:20:28 Five Prime Therapeutics
Post# of 273249
Posted On: 05/09/2014 8:20:29 PM
Five Prime Therapeutics Inc (FPRX) 13.64 $FPRX
Five Prime Therapeutics Announces First Quarter 2014 Financial Results
GlobeNewswire - Thu May 08, 3:48PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today provided a corporate update and reported financial results for the first quarter that ended March 31, 2014.
Five Prime Therapeutics to Announce First Quarter 2014 Financial Results and Host Conference Call on May 8
GlobeNewswire - Thu May 01, 3:12PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, will report its first quarter 2014 financial results on Thursday, May 8, 2014 after the U.S. financial markets close. Five Prime will host a conference call and live audio webcast on Thursday, May 8, 2014 at 5:00 p.m. (ET)/2:00 p.m. (PT) to discuss the company's financial results and provide a general business update.
Bristol-Myers, Samsung BioLogics Extend Ties - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 4:30PM CDT
Bristol-Myers Squibb Company (BMY) expanded its existing manufacturing agreement with Samsung BioLogics.
Should Five Prime Therapeutics (FPRX) Be On Your Radar Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 7:53AM CDT
Five Prime Therapeutics has been witnessing a significant price rise in the past month with a positive momentum in the earnings estimate front
Earnings Estimates Moving Higher for Five Prime (FPRX): Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 7:47AM CDT
Five Prime's stock not only has a decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well, suggesting that it could be a solid choice for investors.
Five Prime Therapeutics to Present at the 13th Annual Needham Healthcare Conference
GlobeNewswire - Tue Apr 01, 5:52PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Aron Knickerbocker, Chief Business Officer, will present at the 13 Annual Needham Healthcare Conference on April 8, 2014 at 4:20 PM Eastern Time. The conference will take place at the Westin Grand Central Hotel in New York City.
Five Prime Therapeutics Announces Upcoming Presentations at the 2014 American Association for Cancer Research Meeting
GlobeNewswire - Thu Mar 27, 6:28PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that data related to FP-1039 (GSK3052230), an FGF ligand trap in a global, multi-arm Phase 1b study, and FPA144, a monoclonal antibody against the FGF receptor 2b, will be presented at the American Association for Cancer Research (AACR) Annual Meeting. The meeting will be held April 5-9, 2014 in San Diego, CA.
Big Pharma's Not-So-Hidden Secret to Success
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 27, 11:05AM CDT
The past week may have been a bit of a bumpy ride for the pharmaceutical and biotech sector following congressional testimony that highlighted the rising cost of branded drugs, but it represents nothing more than a tiny hurdle in what's been an...
Bristol Myers Deal Overshadows Q4 loss at Five Prime - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 10:00AM CDT
Amidst the excitement about the Bristol-Myers deal, Five Prime reported its fourth quarter 2013 results.
Biotech Stock Roundup: GILD Letter Triggers Major Selloff - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 9:13AM CDT
Are the good days over for the biotech sector or is this just a correction?
Five Prime Therapeutics posts higher net loss of USD28.9m in fiscal 2013
M2 - Wed Mar 26, 6:02AM CDT
US-based biotechnology company Five Prime Therapeutics (NasdaqGS:FPRX) stated on Tuesday net loss of USD28.9m (USD5.23 per basic and diluted share) for the year ended 31 December 2013.
Five Prime Therapeutics Announces Fourth Quarter and Fiscal 2013 Financial Results
GlobeNewswire - Tue Mar 25, 3:30PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today provided a corporate update and reported financial results for the fourth quarter and year ended Dec. 31, 2013.
This Week in Biotech: Endocyte Doubles, Intercept Wobbles, and Geron Gets Smacked Again
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 22, 12:45PM CDT
With the SPDR S&P Biotech Index up 57% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Earnings Release and Presentation Schedules, Nominations, and Financial Results - Analyst Notes on Five Prime Therapeutics, Acceleron, Emergent BioSolutions, CONMED, and ImmunoGen
PR Newswire - Fri Mar 21, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Five Prime Therapeutics, Inc. (NASDAQ: FPRX), Acceleron Pharma Inc. (NASDAQ: XLRN), Emergent BioSolutions Inc. (NYSE: EBS), CONMED Corporation (NASDAQ: CNMD), and ImmunoGen, Inc. (NASDAQ: IMGN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Five Prime Therapeutics to Present at Future Leaders in the Biotech Industry
GlobeNewswire - Thu Mar 20, 3:12PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Lewis T. "Rusty" Williams, M.D., Ph.D., President and Chief Executive Officer of Five Prime, will present at the 21 Annual Future Leaders in the Biotech Industry conference on Friday, March 28, at 8:30 a.m. Eastern Time. The conference will take place at the Millennium Broadway Hotel in New York City.
Biotech Stock Roundup: Biogen Up for S&P100, Geron Plunges on Clinical Hold - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 19, 12:27PM CDT
Last week's highlights include Biogen's addition to S&P100, the FDA clinical hold on Geron's sole pipeline candidate and an improved outlook from Alexion.
Can the Uptrend Continue for Five Prime (FPRX)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 8:27AM CDT
Can the Uptrend Continue for Five Prime (FPRX)?
Five Prime, Bristol-Myers Squibb Cut $350M Immuno-Oncology Deal
Ben Fidler, The Motley Fool - Motley Fool - Tue Mar 18, 5:30PM CDT
Five Prime Therapeutics didn't spring out of the blocks like many of the other members of biotech's IPO class of 2013 . But the South San Francisco, CA-based biotech is now having its day in the sun, because it just cut a deal worth up to $350...
Bristol-Myers, Five Prime Join Forces, Shares up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 18, 11:00AM CDT
In a bid to strengthen its oncology pipeline, Bristol-Myers inked a deal with Five Prime
Five Prime Therapeutics (FPRX) Surges: Stock Moves 22.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 18, 8:18AM CDT
Five Prime Therapeutics, Inc. (FPRX) was a big mover last session, as the company saw its shares rise by roughly 23% on the day.
Five Prime Therapeutics Announces First Quarter 2014 Financial Results
GlobeNewswire - Thu May 08, 3:48PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today provided a corporate update and reported financial results for the first quarter that ended March 31, 2014.
Five Prime Therapeutics to Announce First Quarter 2014 Financial Results and Host Conference Call on May 8
GlobeNewswire - Thu May 01, 3:12PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, will report its first quarter 2014 financial results on Thursday, May 8, 2014 after the U.S. financial markets close. Five Prime will host a conference call and live audio webcast on Thursday, May 8, 2014 at 5:00 p.m. (ET)/2:00 p.m. (PT) to discuss the company's financial results and provide a general business update.
Bristol-Myers, Samsung BioLogics Extend Ties - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 4:30PM CDT
Bristol-Myers Squibb Company (BMY) expanded its existing manufacturing agreement with Samsung BioLogics.
Should Five Prime Therapeutics (FPRX) Be On Your Radar Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 7:53AM CDT
Five Prime Therapeutics has been witnessing a significant price rise in the past month with a positive momentum in the earnings estimate front
Earnings Estimates Moving Higher for Five Prime (FPRX): Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 7:47AM CDT
Five Prime's stock not only has a decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well, suggesting that it could be a solid choice for investors.
Five Prime Therapeutics to Present at the 13th Annual Needham Healthcare Conference
GlobeNewswire - Tue Apr 01, 5:52PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Aron Knickerbocker, Chief Business Officer, will present at the 13 Annual Needham Healthcare Conference on April 8, 2014 at 4:20 PM Eastern Time. The conference will take place at the Westin Grand Central Hotel in New York City.
Five Prime Therapeutics Announces Upcoming Presentations at the 2014 American Association for Cancer Research Meeting
GlobeNewswire - Thu Mar 27, 6:28PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that data related to FP-1039 (GSK3052230), an FGF ligand trap in a global, multi-arm Phase 1b study, and FPA144, a monoclonal antibody against the FGF receptor 2b, will be presented at the American Association for Cancer Research (AACR) Annual Meeting. The meeting will be held April 5-9, 2014 in San Diego, CA.
Big Pharma's Not-So-Hidden Secret to Success
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 27, 11:05AM CDT
The past week may have been a bit of a bumpy ride for the pharmaceutical and biotech sector following congressional testimony that highlighted the rising cost of branded drugs, but it represents nothing more than a tiny hurdle in what's been an...
Bristol Myers Deal Overshadows Q4 loss at Five Prime - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 10:00AM CDT
Amidst the excitement about the Bristol-Myers deal, Five Prime reported its fourth quarter 2013 results.
Biotech Stock Roundup: GILD Letter Triggers Major Selloff - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 9:13AM CDT
Are the good days over for the biotech sector or is this just a correction?
Five Prime Therapeutics posts higher net loss of USD28.9m in fiscal 2013
M2 - Wed Mar 26, 6:02AM CDT
US-based biotechnology company Five Prime Therapeutics (NasdaqGS:FPRX) stated on Tuesday net loss of USD28.9m (USD5.23 per basic and diluted share) for the year ended 31 December 2013.
Five Prime Therapeutics Announces Fourth Quarter and Fiscal 2013 Financial Results
GlobeNewswire - Tue Mar 25, 3:30PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today provided a corporate update and reported financial results for the fourth quarter and year ended Dec. 31, 2013.
This Week in Biotech: Endocyte Doubles, Intercept Wobbles, and Geron Gets Smacked Again
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 22, 12:45PM CDT
With the SPDR S&P Biotech Index up 57% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Earnings Release and Presentation Schedules, Nominations, and Financial Results - Analyst Notes on Five Prime Therapeutics, Acceleron, Emergent BioSolutions, CONMED, and ImmunoGen
PR Newswire - Fri Mar 21, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Five Prime Therapeutics, Inc. (NASDAQ: FPRX), Acceleron Pharma Inc. (NASDAQ: XLRN), Emergent BioSolutions Inc. (NYSE: EBS), CONMED Corporation (NASDAQ: CNMD), and ImmunoGen, Inc. (NASDAQ: IMGN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Five Prime Therapeutics to Present at Future Leaders in the Biotech Industry
GlobeNewswire - Thu Mar 20, 3:12PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Lewis T. "Rusty" Williams, M.D., Ph.D., President and Chief Executive Officer of Five Prime, will present at the 21 Annual Future Leaders in the Biotech Industry conference on Friday, March 28, at 8:30 a.m. Eastern Time. The conference will take place at the Millennium Broadway Hotel in New York City.
Biotech Stock Roundup: Biogen Up for S&P100, Geron Plunges on Clinical Hold - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 19, 12:27PM CDT
Last week's highlights include Biogen's addition to S&P100, the FDA clinical hold on Geron's sole pipeline candidate and an improved outlook from Alexion.
Can the Uptrend Continue for Five Prime (FPRX)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 8:27AM CDT
Can the Uptrend Continue for Five Prime (FPRX)?
Five Prime, Bristol-Myers Squibb Cut $350M Immuno-Oncology Deal
Ben Fidler, The Motley Fool - Motley Fool - Tue Mar 18, 5:30PM CDT
Five Prime Therapeutics didn't spring out of the blocks like many of the other members of biotech's IPO class of 2013 . But the South San Francisco, CA-based biotech is now having its day in the sun, because it just cut a deal worth up to $350...
Bristol-Myers, Five Prime Join Forces, Shares up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 18, 11:00AM CDT
In a bid to strengthen its oncology pipeline, Bristol-Myers inked a deal with Five Prime
Five Prime Therapeutics (FPRX) Surges: Stock Moves 22.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 18, 8:18AM CDT
Five Prime Therapeutics, Inc. (FPRX) was a big mover last session, as the company saw its shares rise by roughly 23% on the day.
(0)
(0)Scroll down for more posts ▼